The number of people with susceptibility test result for rifampicin in Trinidad and Tobago
Trinidad and Tobago: The number of people with susceptibility test result for rifampicin was 59.38 in 2021. ▼ Falling
Latest (2021)
59.38
Change on year
down 19.3%
World rank
110th
of 146 countries
All-time high
96.79
in 2018
All-time low
57.76
in 2017
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Trinidad and Tobago, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Trinidad and Tobago recorded 59.38 for the number of people with susceptibility test result for rifampicin in 2021.
That represents a change of down 19.3% on the previous year and up 2.8% over five years.
Trinidad and Tobago ranks 110th of 146 countries on this measure, in the bottom quarter.
The number of people with susceptibility test result for rifampicin in Trinidad and Tobago, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 57.76 | — |
| 2018 | 96.79 | +67.6% |
| 2019 | 66.18 | -31.6% |
| 2020 | 73.6 | +11.2% |
| 2021 | 59.38 | -19.3% |
Trinidad and Tobago compared with similar countries
- Trinidad and Tobago's 59.38 is below the median for high income countries, which is 92.6, 64% of the median. (56 countries reporting)
- Trinidad and Tobago's 59.38 is above the median for Latin America & Caribbean, which is 59.38, 1.0× the median. (21 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 73.58 | 57.76 | 96.79 | 3 |
| 2020s | 66.49 | 59.38 | 73.6 | 2 |
Countries ranked near Trinidad and Tobago
More health data for Trinidad and Tobago
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1463 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,638 deaths per 1,000 people (2090)
- Number of infants who die before age 1 24 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.35 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0263 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.36 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Trinidad and Tobago?
- The number of people with susceptibility test result for rifampicin in Trinidad and Tobago was 59.38 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Trinidad and Tobago?
- The highest recorded value was 96.79 in 2018.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Trinidad and Tobago?
- The lowest recorded value was 57.76 in 2017.
- How does Trinidad and Tobago rank for the number of people with susceptibility test result for rifampicin?
- Trinidad and Tobago ranks 110th out of 146 countries with data for 2021.
- Where does this Trinidad and Tobago data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).